Marcelo E Andia1, Prakash Saha1, Julia Jenkins1, Bijan Modarai1, Andrea J Wiethoff1, Alkystis Phinikaridou1, Steven P Grover1, Ashish S Patel1, Tobias Schaeffter1, Alberto Smith1, Rene M Botnar1. 1. Division of Imaging Sciences and Biomedical Engineering, School of Medicine, St Thomas' Hospital, King's College London, London, Received on: May 3, 2013; final version accepted on: April 1, 2014. United Kingdom (M.E.A., A.J.W., A.P., T.S., R.M.B.); Academic Department of Surgery, Cardiovascular Division (P.S., J.J., B.M., S.P.G., A.S.P., A.S.), Wellcome Trust and EPSRC Medical Engineering Centre (T.S., R.M.B.), BHF Centre of Excellence, Cardiovascular Division (T.S., A.S., R.M.B.), and NIHR Biomedical Research Centre, GSTT (T.S., A.S., R.M.B.), School of Medicine, King's College London, London, United Kingdom; and Radiology Department, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile (M.E.A.).
Abstract
OBJECTIVE: Deep venous thrombosis is a major health problem. Thrombolytic therapies are effective in recanalizing the veins and preventing post-thrombotic complications, but there is no consensus on selection criteria. The aim of this study was to investigate a fibrin-specific MRI contrast agent (EP-2104R) for the accurate quantification of thrombus' fibrin content in vivo and for the identification of thrombus suitable for thrombolysis. APPROACH AND RESULTS: Venous thrombosis was induced in the inferior vena cava of 8- to 10-week-old male BALB/C mice and MRI performed 2, 4, 7, 10, 14, and 21 days later. Eighteen mice were scanned at each time point pre and 2 hours post injection of EP-2104R (8.0 μmol/kg) with 12 mice at each time point used to correlate fibrin contrast uptake with thrombus' histological stage and fibrin content. Six mice at each time point were immediately subjected to intravascular thrombolytic therapy (10 mg/kg of tissue-type plasminogen activator). Mice were imaged to assess response to lytic therapy 24 hours after thrombolytic treatment. Two mice at each time point were scanned post injection of 0.2 mmol/kg of Gd-DTPA (gadolinium with diethylenetriaminepentacetate, Magnevist, Schering AG, Berlin, Germany) for control purpose. Contrast uptake was correlated positively with the fibrin content of the thrombus measured by Western blotting (R(2)=0.889; P<0.001). Thrombus relaxation rate (R1) post contrast and the change in visualized thrombus size on late gadolinium enhancement inversion recovery MRI pre-EP-2104R and post-EP-2104R injection were the best predictors for successful thrombolysis (area under the curve, 0.989 [95% confidence interval, 0.97-1.00] and 0.994 [95% confidence interval, 0.98-1.00] respectively). CONCLUSIONS: MRI with a fibrin-specific contrast agent accurately estimates thrombus fibrin content in vivo and identifies thrombi that are amenable for thrombolysis.
OBJECTIVE: Deep venous thrombosis is a major health problem. Thrombolytic therapies are effective in recanalizing the veins and preventing post-thrombotic complications, but there is no consensus on selection criteria. The aim of this study was to investigate a fibrin-specific MRI contrast agent (EP-2104R) for the accurate quantification of thrombus' fibrin content in vivo and for the identification of thrombus suitable for thrombolysis. APPROACH AND RESULTS: Venous thrombosis was induced in the inferior vena cava of 8- to 10-week-old male BALB/C mice and MRI performed 2, 4, 7, 10, 14, and 21 days later. Eighteen mice were scanned at each time point pre and 2 hours post injection of EP-2104R (8.0 μmol/kg) with 12 mice at each time point used to correlate fibrin contrast uptake with thrombus' histological stage and fibrin content. Six mice at each time point were immediately subjected to intravascular thrombolytic therapy (10 mg/kg of tissue-type plasminogen activator). Mice were imaged to assess response to lytic therapy 24 hours after thrombolytic treatment. Two mice at each time point were scanned post injection of 0.2 mmol/kg of Gd-DTPA (gadolinium with diethylenetriaminepentacetate, Magnevist, Schering AG, Berlin, Germany) for control purpose. Contrast uptake was correlated positively with the fibrin content of the thrombus measured by Western blotting (R(2)=0.889; P<0.001). Thrombus relaxation rate (R1) post contrast and the change in visualized thrombus size on late gadolinium enhancement inversion recovery MRI pre-EP-2104R and post-EP-2104R injection were the best predictors for successful thrombolysis (area under the curve, 0.989 [95% confidence interval, 0.97-1.00] and 0.994 [95% confidence interval, 0.98-1.00] respectively). CONCLUSIONS: MRI with a fibrin-specific contrast agent accurately estimates thrombus fibrin content in vivo and identifies thrombi that are amenable for thrombolysis.
Authors: Marcus Katoh; Patrick Haage; Andrea J Wiethoff; Rolf W Günther; Arno Bücker; Josef Tacke; Elmar Spuentrup Journal: Invest Radiol Date: 2009-03 Impact factor: 6.016
Authors: Ulrike Blume; James Orbell; Matthew Waltham; Alberto Smith; Reza Razavi; Tobias Schaeffter Journal: MAGMA Date: 2009-11-28 Impact factor: 2.310
Authors: Elmar Spuentrup; Arno Buecker; Marcus Katoh; Andrea J Wiethoff; Edward C Parsons; Rene M Botnar; Robert M Weisskoff; Philip B Graham; Warren J Manning; Rolf W Günther Journal: Circulation Date: 2005-02-28 Impact factor: 29.690
Authors: Clive Kearon; Susan R Kahn; Giancarlo Agnelli; Samuel Goldhaber; Gary E Raskob; Anthony J Comerota Journal: Chest Date: 2008-06 Impact factor: 9.410
Authors: Elmar Spuentrup; Rene M Botnar; Andrea J Wiethoff; Tareq Ibrahim; Sebastian Kelle; Marcus Katoh; Murat Ozgun; Eike Nagel; Josef Vymazal; Phil B Graham; Rolf W Günther; David Maintz Journal: Eur Radiol Date: 2008-04-19 Impact factor: 5.315
Authors: Josef Vymazal; Elmar Spuentrup; Gerardo Cardenas-Molina; Andrea J Wiethoff; Michael G Hartmann; Peter Caravan; Edward C Parsons Journal: Invest Radiol Date: 2009-11 Impact factor: 6.016
Authors: Francesco Blasi; Bruno L Oliveira; Tyson A Rietz; Nicholas J Rotile; Pratap C Naha; David P Cormode; David Izquierdo-Garcia; Ciprian Catana; Peter Caravan Journal: Arterioscler Thromb Vasc Biol Date: 2015-08-13 Impact factor: 8.311
Authors: René M Botnar; Julia Brangsch; Carolin Reimann; Christian H P Janssen; Reza Razavi; Bernd Hamm; Marcus R Makowski Journal: J Am Heart Assoc Date: 2018-05-30 Impact factor: 5.501
Authors: Francesco Blasi; Bruno L Oliveira; Tyson A Rietz; Nicholas J Rotile; Helen Day; Pratap C Naha; David P Cormode; David Izquierdo-Garcia; Ciprian Catana; Peter Caravan Journal: J Nucl Med Date: 2015-05-14 Impact factor: 10.057
Authors: Dominik Nörenberg; Hans U Ebersberger; Gerd Diederichs; Bernd Hamm; René M Botnar; Marcus R Makowski Journal: Eur Radiol Date: 2015-07-03 Impact factor: 5.315